Sudhakiranmayi Kuravi

ORCID: 0000-0003-3417-8061
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Receptor Mechanisms and Signaling
  • Ubiquitin and proteasome pathways
  • Acute Myeloid Leukemia Research
  • FOXO transcription factor regulation
  • Lung Cancer Treatments and Mutations
  • Viral-associated cancers and disorders
  • Cellular transport and secretion
  • Protein Kinase Regulation and GTPase Signaling
  • Protein Degradation and Inhibitors
  • Cutaneous lymphoproliferative disorders research
  • Histone Deacetylase Inhibitors Research
  • Cancer-related gene regulation
  • Chronic Myeloid Leukemia Treatments
  • bioluminescence and chemiluminescence research
  • Neurobiology and Insect Physiology Research
  • Cancer-related molecular mechanisms research
  • Sex work and related issues
  • Retinal Development and Disorders
  • Circular RNAs in diseases
  • CAR-T cell therapy research
  • Natural Compounds in Disease Treatment
  • T-cell and Retrovirus Studies
  • Neuroscience and Neuropharmacology Research
  • Epigenetics and DNA Methylation

University of Kansas Medical Center
2013-2022

The University of Kansas Cancer Center
2016-2021

Augusta University Health
2011

Augusta University
2009-2010

Abstract Papillary thyroid carcinoma (PTC) demonstrates significantly reduced patient survival with metastatic progression. Tumor progression can be influenced by metabolism, including antioxidant glutathione (GSH). Glutathione peroxidase 4 (GPX4) is a selenoenzyme that uses GSH as co-factor to regulate lipid peroxidation of cell membranes during increased oxidative stress. GPX4 suppression in tumor cells induce ferroptosis. This study aims examine ferroptosis potentially critical pathway...

10.1038/s41598-022-23906-2 article EN cc-by Scientific Reports 2022-11-12

G-protein heterotrimers, composed of a guanine nucleotide-binding Gα subunit and an obligate Gβγ dimer, regulate signal transduction pathways by cycling between GDP- GTP-bound states. Signal deactivation is achieved Gα-mediated GTP hydrolysis (GTPase activity) which enhanced the GTPase-accelerating protein (GAP) activity “regulator signaling” (RGS) proteins. In cellular context, RGS proteins have also been shown to speed up onset signaling, accelerate without changing amplitude or...

10.1073/pnas.0912934107 article EN Proceedings of the National Academy of Sciences 2010-03-29

Arginine methylation is a common post-translational modification, but its role in regulating protein function poorly understood. This study demonstrates that, TNF receptor-associated factor 6 (TRAF6), an E3 ubiquitin ligase involved innate immune signaling, regulated by reversible arginine range of primary and cultured cells. Under basal conditions, TRAF6 methylated the methyltransferase PRMT1, this inhibits activity, reducing activation toll-like receptor signaling. In response to ligands,...

10.1074/jbc.m115.653543 article EN cc-by Journal of Biological Chemistry 2015-07-29

Hepatitis C virus (HCV) infection produces chronic liver injury that is significantly exacerbated by alcohol consumption. While multiple mechanisms contribute to this synergy, a viral-induced loss of antioxidant responses has been shown play an important role. This study examined the effects HCV and on regulation transcription factor FOXO3, regulator Mn-superoxide dismutase (SOD2) expression, tumor suppressor, component hepatic response system. FOXO3 was activated either or alone but...

10.1002/hep.26618 article EN Hepatology 2013-07-15

G protein-coupled receptors (GPCRs) self-associate as dimers or higher-order oligomers in living cells. The stability of associated GPCRs has not been extensively studied, but it is generally thought that these move between the plasma membrane and intracellular compartments intact oligomers. Here we show β2-adrenergic (β2ARs) at can dissociate during agonist-induced internalization. We use bioluminescence-resonance energy transfer (BRET) to monitor movement β2ARs subcellular compartments....

10.1371/journal.pone.0017361 article EN cc-by PLoS ONE 2011-02-22

More than 80% of anaplastic lymphoma kinase (ALK)-positive large cell (ALCL) patients harbor the (nucleophosmin) NPM1-ALK fusion gene t(2;5) chromosomal translocation. We evaluated preclinical and clinical efficacy ceritinib treatment this aggressive lymphoma.We studied effects in NPM1-ALK+ T-cell lines vitro on tumor size survival advantage vivo utilizing xenografts. treated an ALCL patient with ceritinib. reviewed all hematologic malignancies profiled by a hybrid-capture next-generation...

10.1016/j.esmoop.2021.100172 article EN cc-by-nc-nd ESMO Open 2021-07-07

Epstein-Barr virus (EBV) is directly implicated in several B-cell lymphoid malignancies. EBV-associated lymphomas are characterized by prominent activation of the NF-κB pathway and targeting this establishes a rationale for therapeutic approach. The ubiquitin/proteasome signaling plays an essential role regulation pathway. Ixazomib FDA-approved, orally bioavailable proteasome inhibitor. Here we report first preclinical evaluation ixazomib-mediated growth-inhibitory effects on EBV-infected...

10.1158/1541-7786.mcr-18-0924 article EN Molecular Cancer Research 2018-11-28

Gene fusions are known to drive many human cancers. Therefore, the functional characterization of newly discovered is critical understanding oncobiology these tumors and enable therapeutic development. NPM1-TYK2 a novel fusion identified in CD30 + lymphoproliferative disorders, here we present evaluation this gene as an oncogene. The chimeric protein consists amino-terminus nucleophosmin 1 (NPM1) carboxyl-terminus tyrosine kinase 2 (TYK2), including domain. Using vitro lymphoid cell...

10.1038/s41698-021-00246-4 article EN cc-by npj Precision Oncology 2022-01-18

Abstract Anaplastic large cell lymphoma (ALCL) is an aggressive type of non-Hodgkin lymphoma. More than three-fourths anaplastic kinase (ALK)-positive ALCL cases express the nucleophosmin 1 (NPM1)-ALK fusion gene as a result t(2;5) chromosomal translocation. The homodimerization NPM1-ALK protein mediates constitutive activation chimeric tyrosine activity and downstream signaling pathways responsible for proliferation survival. Gilteritinib inhibitor recently approved by FDA treatment...

10.1158/1541-7786.mcr-20-0738 article EN Molecular Cancer Research 2021-01-29

Abstract Objectives: Acute myeloid leukemia (AML) is a heterogeneous disease with diverse genetic abnormalities present in all ages, but mainly prevalent an elderly population average age of above 60 years. The treatment AML remains formidable challenge as the long-term outcomes patients have not improved last three decades, ≤5% overall survival recorded at 5 years, calling for novel options. Epigenetic therapy has significant impact on management hematologic malignancies. Recent findings...

10.1158/1538-7445.am2018-4821 article EN Cancer Research 2018-07-01

Epstein-Barr virus (EBV) is directly implicated in several B-cell lymphoid malignancies. EBV associated neoplasms occur both organ and allogeneic hematopoietic stem cell transplantations due to immunosuppression these patients maintain the function of transplant. Treatment limited reduction antineoplastic chemotherapy. lymphomas are characterized by prominent activation Nuclear Factor kappa (NF-kB) pathway targeting this establishes a rationale for therapeutic approach. The...

10.1158/1538-7445.am2016-3079 article EN Cancer Research 2016-07-15

Abstract Anaplastic large cell lymphoma (ALCL) is an aggressive CD30+ T-Cell that accounts for 2-8% and 10-15% non-Hodgkin lymphomas in adults children, respectively. The currently used standard therapy anaplastic kinase (ALK, a member of insulin receptor superfamily) positive ALCL has limited effectiveness, resulting substantial percentage cases with poor outcome, either failing to enter remission or relapsing within few months after starting the treatment. Thus, there clear unmet clinical...

10.1158/1538-7445.am2015-776 article EN Cancer Research 2015-08-01
Coming Soon ...